Elucid Bioimaging, Inc. of Boston received 1 citation after the Food and Drug Administration (FDA) inspected its device operations and post-market procedures on March 20, as noted by data published on the FDA’s website.
Elucid Bioimaging, Inc. in Boston underwent a March 20 FDA inspection focused on device compliance and post-market device assurance, as noted in data available on the FDA’s website.
Medicaid providers in Holyoke submitted $35,602,799 in claims for services categorized under National Codes Established for State Medicaid Agencies in 2024, representing a 53.4% rise from the prior year.
Springfield Medicaid providers billed $110,985,631 for services under the National Codes Established for State Medicaid Agencies category in 2024, showing an 18.6% rise over the prior year.
In 2024, Chelsea providers billed $1,588,640 for Medicaid services under the National Codes Established for State Medicaid Agencies, reflecting a 40.3% increase over the prior year.
Medicaid spending tied to the Temporary National Codes (Non-Medicare) category in Revere increased by 20.7% in 2024, signaling shifts in service use and reimbursement approaches.
Boston’s Medicaid expenditures for services under the National Codes Established for State Medicaid Agencies rose 9% to $191.6 million in 2024, signaling shifts in usage and payment structures.
COVID-19 services accounted for under 0.1% of all Medicaid spending in Boston in 2024, totaling a minimum of $691,711 for claims linked with virus-specific HCPCS codes.
Medicaid payments for services in the Alcohol and Drug Abuse Treatment category rose 0.3% statewide in Massachusetts during 2024, illustrating shifts in how care was used and reimbursed.
Massachusetts saw Medicaid payments for Temporary National Codes (Non-Medicare) services rise by 6.2% in 2024, reflecting shifts in service use and payment structures statewide.